Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 58.78% is 445% above its 3-year average of 10.78%, near the high end of its 3-year range (0.00%–58.78%).
109.63% above its 12-month average of 28.04%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 23.43%.
GROSS MARGIN
58.78%
GROSS MARGIN AVG TTM
28.04%
GROSS MARGIN AVG 3Y
10.78%
GROSS MARGIN AVG 5Y
0.00%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+109.63%
CURRENT VS 3Y AVG
+445.04%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.38%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+42.05%
vs the sector median at left
NRx Pharmaceuticals, Inc.
Market Cap
$127.94M
Gross Margin
58.78%
TTM Avg
28.04%
3Y Avg
10.78%
5Y Avg
0.00%
Market Cap
$128.43M
Gross Margin
82.77%
TTM Avg
89.91%
3Y Avg
44.96%
5Y Avg
29.97%
Market Cap
$125.14M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$131.83M
Gross Margin
33.47%
TTM Avg
39.70%
3Y Avg
43.04%
5Y Avg
44.80%
Market Cap
$124.84M
Gross Margin
34.65%
TTM Avg
28.86%
3Y Avg
24.17%
5Y Avg
16.11%
Market Cap
$132.66M
Gross Margin
57.63%
TTM Avg
59.89%
3Y Avg
61.87%
5Y Avg
62.78%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| NRx Pharmaceuticals, Inc. (NRXP) | $127.94M | 58.78% | 28.04% | 10.78% | 0.00% |
| Pyxis Oncology, Inc. (PYXS)vs › | $128.43M | 82.77% | 89.91% | 44.96% | 29.97% |
| Entera Bio Ltd. (ENTX)vs › | $126.92M | 0.00% | 2.48% | -4.54% | 5.72% |
| TuHURA Biosciences, Inc. (HURA)vs › | $125.14M | 0.00% | 0.00% | 0.00% | 0.00% |
| Health Catalyst, Inc. (HCAT)vs › | $131.83M | 33.47% | 39.70% | 43.04% | 44.80% |
| Tonix Pharmaceuticals Holding Corp. (TNXP)vs › | $124.84M | 34.65% | 28.86% | 24.17% | 16.11% |
| AirSculpt Technologies, Inc. (AIRS)vs › | $132.66M | 57.63% | 59.89% | 61.87% | 62.78% |
| LifeMD, Inc. (LFMD)vs › | $133.24M | 85.91% | 84.21% | 85.09% | 82.87% |
| Freenome, Inc. (FRNM)vs › | $132.64M | N/A | N/A | N/A | N/A |
| Cibus, Inc. (CBUS)vs › | $122.13M | -62.76% | -61.84% | -230.63% | -163.28% |
Gross Margin
58.8%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 23.43% |
| 2026-03-31 | 25.47% |
| 2025-12-31 | 48.32% |
| 2025-09-30 | 42.98% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 0.00% |
| 2019-03-31 | 0.00% |
| 2018-12-31 | 0.00% |
| 2018-09-30 | 0.00% |
| 2018-06-30 | 0.00% |
| 2018-03-31 | 0.00% |
| 2017-12-31 | 0.00% |
| 2017-09-30 | 0.00% |
